Alpha MOS (FR0013421286 ALNEO), world leader in smell, taste and visual industrial instrument analyzers, announces the on-schedule completion of the 2nd clinical study on the non-invasive breath glucose monitoring device developed by its Medtech subsidiary, BOYDSense.
The study, promoted by Toulouse University Hospital (CHU) and launched in late 2021 by the Diabetology, Metabolic Diseases and Nutrition research team, involved 130 patients with type 2 diabetes. The results will be the subject of scientific publications by the CHU and BOYDSense in the coming months.
The study was conducted in two phases. During the first phase, data were collected to develop the first embedded algorithm for measuring blood glucose by breath analysis. In the second phase, the device equipped with this algorithm was used by 30 patients to perform repeated glucose measurements. This scientific approach not only enabled continuous data collection for further development of the system, but also confirmed the potential of this radically innovative glucose measurement technique.
“This new non-invasive approach could soon offer a very attractive alternative to capillary glycemic monitoring for people with diabetes” says Prof. Pierre Gourdy, diabetologist at the University Hospital of Toulouse and principal investigator of the study.
Pending publication of more detailed results, BOYDSense can already announce that the clinical study has met its objectives, namely to:
- Establish successful system with functional testing;
- Confirm patients’ interest in this new device, as illustrated by the number and enthusiasm of study participants;
- Validate previous developments;
- Gather new data that has helped improve the algorithms since the beginning of the test phase.
« The conclusion of the study conducted by the Toulouse University Hospital represents an important milestone in the development of our innovative solution aimed at improving the daily lives of people with diabetes. The data collected has enabled us to improve the performance of our device and the associated application, so that we can carry out increasingly precise tests and bring us closer to a future market launch. I would like to thank the CHU research team and the many patients who took part in the study. » says Ben Delhey, CEO of BOYDSense.